This advertisement has not loaded yet, but your article continues below. ZURICH — Investment group EQT and members of the Struengmann family, who are investors in Biontech , are considering a joint bid for Swiss pharamceutical group Novartis’ generics division Sandoz, German newspaper Handelsblatt reported on Friday, citing unnamed sources. A potential offer could value Sandoz at more than 20 billion Swiss francs ($21.58 billion), the newspaper reported. ($1 = 0.9268 Swiss francs) (Reporting by Brenna Hughes Neghaiwi Editing by Riham Alkousaa) This advertisement has not loaded yet, but your article continues below.
https://financialpost.com/pmn/business-pmn/eqt-biontech-investor-family-consider-sandoz-bid-handelsblatt
EQT, Biontech investor family consider Sandoz bid
